NICHD-2012-STA01 was a multiple center, open label, multiple-dose pharmacokinetic study. The primary objective of this study was to determine the pharmacokinetics (PK) of rifampin, ticarcillin-clavula

NIAID Data Ecosystem10

Physical Examination Dataset in Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants (<91 days) with Suspected or Complicated Intra-abdominal Infections

腹腔感染治疗

药代动力学

Timing and findings of physical exam, including system review and conditions or abnormalities Study Description An open-label, multiple-dose study to determine the safety, tolerability, and pharmacoki

NIAID Data Ecosystem30

Dataset from Phase 1, Multicenter, Open Label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2 Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer

HER2阳性癌症治疗

药代动力学

HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells. This study will test an e

NIAID Data Ecosystem10